drugset / Trial / NCT04448223

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

NCT04448223

Phase 2 Unknown 100 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of CKD-351

Timeline

Start
2020-06-11
Primary completion
2022-12-05
Completion
2022-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dorzolamide Small molecule 20 mg/ml
Subject Latanoprost Small molecule 25 ug/ml
Subject Latanoprost Small molecule 50 ug/ml